The European Medicines Agency (EMEA) orphan drug designation program is dedicated to stimulate and support the development of pharmaceuticals to treat life-threatening or very serious and rare diseases, which cannot be treated or can only be treated insufficiently.
Alfred Bach, CEO of Sygnis Pharma, said: “We will plan further steps in close cooperation with EMEA and hope to initiate clinical trials within the next twelve months.”